<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00965549</url>
  </required_header>
  <id_info>
    <org_study_id>LANTU_L_04211</org_study_id>
    <secondary_id>2008-007026-19(EudraCT)</secondary_id>
    <nct_id>NCT00965549</nct_id>
  </id_info>
  <brief_title>Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients</brief_title>
  <acronym>LanScape</acronym>
  <official_title>Comparison of a Basal Plus One Insulin Regimen (Insulin Glargine/Insulin Glulisine) With a Biphasic Insulin Regimen (Insulin Aspart/Insulin Aspart Protamine 30/70) in Type 2 Diabetes Patients Following Basal Insulin Optimisation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The primary objective is to demonstrate the non-inferiority at six months of a basal plus one
      insulin regimen (Lantus plus one injection of Apidra) compared with a biphasic insulin
      regimen (NovoMix 30) at controlling glycosylated haemoglobin (HbA1c) in type 2 diabetes.

      The secondary objective are:

        -  To compare the proportion of patients in each treatment group reaching HbA1c target (&lt;
           7%) at the end of the treatment period

        -  To compare the rates of hypoglycaemia (total, severe, nocturnal)

        -  To compare the change in body weight from visit 10 to visit 24

        -  To compare the change in diabetes specific quality of life and other patient reported
           outcomes from visit 10 to visit 24

             -  Diabetes Treatment Satisfaction Questionnaire - status and change (DTSQs+c)

             -  Audit of Diabetes-Dependent Quality of Life (ADDQoL) questionnaire

             -  Insulin Treatment Satisfaction Questionnaire (ITSQ)

             -  EuroQoL 5 Dimensions (EQ5D) questionnaire

        -  To record the change in the daily dose of insulin from visit 2 to visit 10 and visit 10
           to visit 24
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycosylated Haemoglobin (HbA1c)</measure>
    <time_frame>At week 7 and week 32</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>At week 8 and week 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes specific quality of life measured using ADDQoL (Audit of Diabetes-Dependent Quality of Life questionnaire) and other patient reported outcomes measured using EQ5D (EuroQoL 5 Dimensions questionnaire)</measure>
    <time_frame>Week 8 and week 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycaemia (total, severe and nocturnal)</measure>
    <time_frame>At week 0 and week 32</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">463</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Lantus + Apidra basal plus one</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Before randomization (common with arm 2):
A 1 to 2 weeks of screening period: patients will continue on their current insulin and oral antidiabetic drug (OAD) therapy.
8 weeks of run-in period: patients will switch their treatment for insulin glargine (one daily injection at bedtime) and all OADs (with the exception of metformin) will be discontinued.
After randomization:
24 weeks of treatment period: Insulin (Lantus®) + metformin (if applicable) + a single injection of insulin glulisine (Apidra®), the latter administered at the patients largest meal of the day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NovoMix 30 Biphasic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Before randomization (common with arm 1):
A 1 to 2 weeks of screening period: patients will continue on their current insulin and oral antidiabetic drug (OAD) therapy.
8 weeks of run-in period: patients will switch their treatment for insulin glargine (one daily injection at bedtime) and all OADs (with the exception of metformin) will be discontinued.
After randomization:
24 weeks of treatment period: Insulin aspart/ insulin protamine crystallised insulin aspart (NovoMix® 30) + metformin (if applicable)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INSULIN GLARGINE (HOE901)</intervention_name>
    <description>LANTUS®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)</description>
    <arm_group_label>Lantus + Apidra basal plus one</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin aspart</intervention_name>
    <description>NovoMix® 30: Suspension for injection. 100U/mL in a prefilled pen (FlexPen®)</description>
    <arm_group_label>NovoMix 30 Biphasic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glulisine</intervention_name>
    <description>APIDRA®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)</description>
    <arm_group_label>Lantus + Apidra basal plus one</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Type 2 diabetes mellitus

          -  Patients being treated with Lantus once daily, Levemir once or twice daily or NPH
             insulin once or twice daily as a single insulin for at least three months 10.0% &gt; or =
             HbA1c &gt; or = 7.5%

          -  BMI &lt; or = 40 kg/m²

          -  If patients are taking oral antidiabetics (OADs), the dose must be stable for at least
             1 month

          -  Ability and willingness to perform blood glucose monitoring using a blood glucose
             meter and ability and willingness to use a patient diary

          -  Provision of written informed obtained prior to enrollment in the study

        Exclusion criteria:

          -  Type 1 diabetes mellitus

          -  Current or previous treatment with an insulin other than basal insulin (biphasic
             insulin, short acting insulin, rapid-acting insulin analogue)

          -  Treatment with GLP-1 receptor agonists or with DPPIV inhibitors in the 3 months before
             screening

          -  Active proliferative diabetic retinopathy, as defined by the application of
             photocoagulation or surgery, in the 6 months before screening or any other unstable
             (rapidly progressing) retinopathy that may require photocoagulation or surgery during
             the study (confirmed by an optic fundus exam performed in the 2 years prior to
             screening)

          -  Unable or unwilling to enter either of the treatment arms

          -  Women who are pregnant or lactating (women of childbearing potential must have a
             negative pregnancy test at study entry and a medically approved contraceptive method)

          -  History of hypersensitivity to the study drugs or to drugs with a similar chemical
             structure

          -  Treatment with systemic corticosteroids in the 3 months prior to study entry

          -  Treatment with any investigational product in the 2 months prior to study entry

          -  Current treatment with any non-selective beta-blockers

          -  Likelihood of requiring treatment during the study period with drugs not permitted by
             this clinical protocol

          -  Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major
             disease making implementation of the protocol or interpretation of the study results
             difficult

          -  Impaired hepatic function as shown by ALT and/or AST greater than three times the
             upper limit of normal at screening

          -  Impaired renal function as shown by serum creatinine &gt;135 µmol/l in men and &gt; 110
             µmol/l in women at screening

          -  History of drug or alcohol abuse

          -  Mental condition rendering the patient unable to understand the nature, scope and
             possible consequences of the study

          -  Patient unlikely to comply with protocol, e.g. uncooperative attitude, inability to
             return for follow-up visits, or unlikely to complete the study

          -  Patient is the investigator or any sub investigator, research assistant, pharmacist,
             study coordinator, other staff or relative thereof directly involved

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine van Schalkwyk, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 204</name>
      <address>
        <city>Campbelltown</city>
        <zip>2560</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 205</name>
      <address>
        <city>Campbelltown</city>
        <zip>2560</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 201</name>
      <address>
        <city>Caulfield</city>
        <zip>3162</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 210</name>
      <address>
        <city>Daw Park</city>
        <zip>5041</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 214</name>
      <address>
        <city>Douglas</city>
        <zip>4814</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203</name>
      <address>
        <city>Heidelberg</city>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 206</name>
      <address>
        <city>Herston</city>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 211</name>
      <address>
        <city>Maroubra</city>
        <zip>2035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 207</name>
      <address>
        <city>Meadowbrook</city>
        <zip>4131</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 212</name>
      <address>
        <city>Melbourne</city>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 209</name>
      <address>
        <city>Milton</city>
        <zip>4064</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 213</name>
      <address>
        <city>Nowra</city>
        <zip>2541</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 202</name>
      <address>
        <city>Parkville</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 208</name>
      <address>
        <city>Southport</city>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-109</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB251LD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-118</name>
      <address>
        <city>Ashton-under-Lyne</city>
        <zip>OL69RW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-157</name>
      <address>
        <city>Ayr</city>
        <zip>KA66DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-149</name>
      <address>
        <city>Barnsley</city>
        <zip>S752EP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-135</name>
      <address>
        <city>Bath</city>
        <zip>BA13NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-124</name>
      <address>
        <city>Birmingham</city>
        <zip>B187QH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-150</name>
      <address>
        <city>Birmingham</city>
        <zip>B95SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-106</name>
      <address>
        <city>Bournemouth</city>
        <zip>BH77DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-136</name>
      <address>
        <city>Bradford</city>
        <zip>BD96RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-130</name>
      <address>
        <city>Bristol</city>
        <zip>BS105NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-114</name>
      <address>
        <city>Bury St Edmunds</city>
        <zip>IP332QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-132</name>
      <address>
        <city>Carmarthen</city>
        <zip>SA312AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-141</name>
      <address>
        <city>Cheadle</city>
        <zip>SK86LU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-112</name>
      <address>
        <city>Chesterfield</city>
        <zip>S404TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-147</name>
      <address>
        <city>Chester</city>
        <zip>CH21UL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-152</name>
      <address>
        <city>Chichester</city>
        <zip>PO196SE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-159</name>
      <address>
        <city>Cleveleys</city>
        <zip>FY53LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-113</name>
      <address>
        <city>Colchester</city>
        <zip>CO45JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-119</name>
      <address>
        <city>Cornwall</city>
        <zip>TR13LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-162</name>
      <address>
        <city>Crawley</city>
        <zip>RH107DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-145</name>
      <address>
        <city>Dafen</city>
        <zip>SA14 8QF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-165</name>
      <address>
        <city>Dumfries</city>
        <zip>DG14AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-167</name>
      <address>
        <city>Durham</city>
        <zip>DH15TW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-173</name>
      <address>
        <city>East Kilbride</city>
        <zip>G758RG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-105</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH164SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-115</name>
      <address>
        <city>Exeter</city>
        <zip>EX25DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-160</name>
      <address>
        <city>Fleetwood</city>
        <zip>FY76HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-107</name>
      <address>
        <city>Gateshead</city>
        <zip>NE96SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-127</name>
      <address>
        <city>Glasgow</city>
        <zip>G213UW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-174</name>
      <address>
        <city>Haddington</city>
        <zip>EH413PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-164</name>
      <address>
        <city>Hereford</city>
        <zip>HR12RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-126</name>
      <address>
        <city>High Wycombe</city>
        <zip>HP112TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-102</name>
      <address>
        <city>Hull</city>
        <zip>HU32JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-120</name>
      <address>
        <city>Ipswich</city>
        <zip>IP45PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-163</name>
      <address>
        <city>Kirkcaldy</city>
        <zip>KY25AH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-161</name>
      <address>
        <city>Lancaster</city>
        <zip>LA11RP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-101</name>
      <address>
        <city>Liverpool</city>
        <zip>L78XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-108</name>
      <address>
        <city>Liverpool</city>
        <zip>L97AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-122</name>
      <address>
        <city>Livingston</city>
        <zip>EH546PP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-110</name>
      <address>
        <city>Llantrisant</city>
        <zip>CF728XR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-142</name>
      <address>
        <city>London</city>
        <zip>N18 1QX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-123</name>
      <address>
        <city>London</city>
        <zip>N195NF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-166</name>
      <address>
        <city>London</city>
        <zip>W91SP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-137</name>
      <address>
        <city>Manchester</city>
        <zip>M85RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-156</name>
      <address>
        <city>Mortimer</city>
        <zip>RG7 3SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-140</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE46BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-138</name>
      <address>
        <city>Newport</city>
        <zip>PO305TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-133</name>
      <address>
        <city>Nottingham</city>
        <zip>NG72UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-121</name>
      <address>
        <city>Nuneaton</city>
        <zip>CV107DJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-129</name>
      <address>
        <city>Plymouth</city>
        <zip>PL53JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-116</name>
      <address>
        <city>Salford</city>
        <zip>M68HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-143</name>
      <address>
        <city>Scunthorpe</city>
        <zip>DN15 7BH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-104</name>
      <address>
        <city>Sheffield</city>
        <zip>S57AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-103</name>
      <address>
        <city>St Helens</city>
        <zip>WA93DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-139</name>
      <address>
        <city>St Leonards on Sea</city>
        <zip>TN377RD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-111</name>
      <address>
        <city>Stevenage</city>
        <zip>SG14AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-131</name>
      <address>
        <city>Stirling</city>
        <zip>FK82AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-146</name>
      <address>
        <city>Sunderland</city>
        <zip>SR47TP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-128</name>
      <address>
        <city>Westbury</city>
        <zip>BA133JD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826-117</name>
      <address>
        <city>York</city>
        <zip>YO318HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2009</study_first_submitted>
  <study_first_submitted_qc>August 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2009</study_first_posted>
  <last_update_submitted>January 7, 2013</last_update_submitted>
  <last_update_submitted_qc>January 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
    <mesh_term>Protamines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

